Systematic review demonstrates L-glutamine reduces vaso-occlusive crises in sickle cell disease, suggesting potential for improved patient outcomes.
Key Points
L-glutamine reduced vaso-occlusive crises, leading to fewer hospitalizations and enhancing safety in sickle cell disease patients.
A significant improvement was observed with a reduction of -0.75 in VOC frequency and -0.72 in hospitalization rates across 352 patients.
Meta-analysis performed applied a random effect model to derive conclusions from existing studies on L-glutamine's efficacy.
Indicates the need for further large-scale randomized controlled trials to validate long-term safety and efficacy outcomes in sickle cell disease treatment.